ReviewNPJ vaccines2019
The how's and what's of vaccine reactogenicity.
Review in NPJ vaccines, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 322 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety of the Sputnik V Vaccine in Health Personnel of Private Effectors of the City of Buenos Aires, Argentina
Immunity Against the COVID-19 Vaccine in Healthcare Workers of Buenos Aires, Argentine.
Safety and Efficacy of the Coronavirus Disease 2019 Vaccine in Hemodialysis Patients
Who cites it
322 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pneumococcal vaccine for prevention of acute otitis media in children: a meta-analysis.BMC infectious diseases · 2026Pooled it
- Safety of co-administration of injectable vaccines in individuals under 18 years of age: A systematic literature review.Human vaccines & immunotherapeutics · 2025Pooled it
- Pooled it
- Real-world evaluation of 2023-2024 XBB.1.5 mRNA and protein-based COVID-19 vaccine reactogenicity from the randomized BEEHIVE trial.Human vaccines & immunotherapeutics · 2026Trial
- Randomized, placebo-controlled phase 3 trial evaluating safety, immunogenicity, and reactogenicity of RSVPreF3-Mat in high-risk pregnant women and their infants.Human vaccines & immunotherapeutics · 2026Trial
- Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18-49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
- Trial
- Polypore mushroom mycelia as an adjunct to COVID-19 vaccination: a randomized clinical trial.BMC immunology · 2026Trial
- Safety and immunogenicity of the invasive non-typhoidal Salmonella (iNTS)-GMMA vaccine: a first-in-human, randomised, dose escalation trial.EBioMedicine · 2025Trial
- Shared clinical and immunologic features of mRNA vaccines: preliminary results from a comparative clinical study.Frontiers in immunology · 2025Trial
- Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion Maternal Vaccine Coadministered With Diphtheria-Tetanus-Pertussis Vaccine: A Phase 2 Study.The Journal of infectious diseases · 2024Trial
- Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702.Vaccine · 2024Trial
- Physiological Response to the COVID-19 Vaccine: Insights From a Prospective, Randomized, Single-Blinded, Crossover Trial.Journal of medical Internet research · 2024Trial
- Safety of BCG vaccination and revaccination in healthcare workers.Human vaccines & immunotherapeutics · 2023Trial
- Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Association of post-vaccination adverse reactions after influenza vaccine with mortality and cardiopulmonary outcomes in patients with high-risk cardiovascular disease: the INVESTED trial.European journal of heart failure · 2023Trial
- Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023Trial
- Vaccination induces HIV broadly neutralizing antibody precursors in humans.Science (New York, N.Y.) · 2022Trial
- From discovery through emergency use to the present: Safety evaluation of the COVID-19 mRNA-1273 (Moderna) vaccine.Human vaccines & immunotherapeutics · 2026Review
- DTaP-induced infantile epileptic spasms syndrome high-risk window: Insights from school-age children.Human vaccines & immunotherapeutics · 2026Article
262 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reactogenicity represents the physical manifestation of the inflammatory response to vaccination, and can include injection-site pain, redness, swelling or induration at the injection site, as well as systemic symptoms, such as fever, myalgia, or headache. The experience of symptoms following vaccination can lead to needle fear, long-term negative attitudes and non-compliant behaviours, which undermine the public health impact of vaccination. This review presents current knowledge on the potential causes of reactogenicity, and how host characteristics, vaccine administration and composition factors can influence the development and perception of reactogenicity. The intent is to provide an overview of reactogenicity after vaccination to help the vaccine community, including healthcare professionals, in maintaining confidence in vaccines by promoting vaccination, setting expectations for vaccinees about what might occur after vaccination and reducing anxiety by managing the vaccination setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.